Ming, Jie
Yu, Xinwen
Xu, Xiaoqiang
Wang, Li
Ding, Chao
Wang, Zhifeng
Xie, Xuan
Li, Sheli
Yang, Wenjuan
Luo, Shu
He, Qingzhen
Du, Yafang
Tian, Zhufang
Gao, Xiling
Ma, Kaiyan
Fang, Yujie
Li, Chen
Zhao, Jiajun
Wang, Xiaokai
Ji, Qiuhe http://orcid.org/0000-0002-3010-5837
Funding for this research was provided by:
Natural Science Foundation of Shaanxi Province, China (2013KTZB03-02-01)
Key Research and Development Program of Shaanxi Province, China (2017ZDCXLSF0201)
National Key R&D Program (2017YFC1309803)
Article History
Received: 3 June 2020
Accepted: 21 July 2021
First Online: 9 August 2021
Declarations
:
: This study was approved by the independent Ethics Committee of Xijing Hospital, First Affiliated Hospital of the Fourth Military Medical University (ID: KY20150611-3). Each subject provided signed and dated informed consent before conducting any procedure associated with the study. And this study conformed to the principles of the Declaration of Helsinki.
: Not applicable.
: The Northeast Pharmaceutical Group Shenyang First Pharmaceutical Co., Ltd. and Livzon Pharmaceutical Group Inc. provided drugs for free. XX, ZW, and XW are affiliated to Aimigene Institute, which is the research department of Shenzhen 01 Life Science and Technology Ltd. The remaining authors declare that they have no competing interests.